View : 782 Download: 0
Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
- Title
- Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
- Authors
- Seong, Jong-Mi; Shin, Dongho; Sung, Jae Woo; Cho, Shinjay; Yang, Jonghyup; Kang, Sungmin; Moon, Hyong Woo; Lee, Kyu Won; Ha, U-Syn
- Ewha Authors
- 성종미
- SCOPUS Author ID
- 성종미
- Issue Date
- 2020
- Journal Title
- JOURNAL OF CANCER
- ISSN
- 1837-9664
- Citation
- JOURNAL OF CANCER vol. 11, no. 14, pp. 4015 - 4022
- Keywords
- Prostatic Neoplasms; Gonadotropirt-Releasing Hormone; Antiandrogens; Cerebrovascular Disease; Cardiovascular Diseases
- Publisher
- IVYSPRING INT PUBL
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Purpose: To conduct a population-based study to determine whether the use of GnRH agonist and antiandrogens are associated with an increased risk of cardio-cerebrovascular disease (CCVD) in Asian patients with prostate cancer using the National Health Insurance Service-Elderly Cohort Database (NHIS-ECD). Materials and Methods: We included a total of 2,413 men aged 60 years or older with prostate cancer between January 2003 and December 2008. Outcomes of interest included the first occurrence of cardiovascular events [acute myocardial infarction (AMI), ischemic heart disease (IHD)] and cerebrovascular events [ischemic stroke (IS), and cerebrovascular disease (CVD)]. Results: The 5-year AMI-free rates of patients diagnosed with prostate cancer and treated with GnRH agonists, antiandrogens alone, or androgen deprivation therapy (ADT)-naive interventions were 97.0%, 96.5%, and 98.3%, respectively, while the 5-year IHD-free rates were 93.2%, 92.3%, and 94.5%, respectively. Exposure to GnRH agonists or antiandrogen regimens did not significantly increase the risk of AMI or IHD compared to ADT-naive treatment in multivariate Cox proportional-hazards models after adjusting for other covariates. Five-year IS-free rates of patients exposed to GnRH agonists, antiandrogens alone, and those with ADT-naive prostate cancer were 94.8%, 94.7%, and 95.5%, respectively, while the five-year CVD-free rates were 92.9%, 93.3%, and 94.6%, respectively. Cox proportional-hazards models also failed to show that men who received GnRH agonist or antiandrogen treatment alone carried a significantly increased risk for IS or CVD compared to ADT-naive patients. Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naive prostate cancer.
- DOI
- 10.7150/jca.38237
- Appears in Collections:
- 연구기관 > 약학연구소 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML